Please use this identifier to cite or link to this item:
|Title: ||CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma|
|Authors: ||Ts, Hsiao-Chi;Tsai, Hsiao-Chi;Hua, Chun-Yin;Huang, Chun-Yin;Su, Hong-Lin;Su, Hong-Lin;湯智昕;Chih-Hsin, Tang|
|Issue Date: ||2014-06-04 10:16:36 (UTC+8)|
|Abstract: ||Osteosarcoma (OS) is the most common form of malignant bone tumor and is an aggressive malignant neoplasm exhibiting osteoblastic differentiation. Cisplatin is one of the most efficacious antitumor drugs for osteosarcoma patients. However, treatment failures are common due to the development of chemoresistance. CCN2 (also known as CTGF), is a secreted protein that binds to integrins, modulates the invasive behavior of certain human cancer cells. However, the effect of CCN2 in cisplatin-mediated chemotherapy is still unknown. Here, we found that CCN2 was upregulated in human osteosarcoma cells after treatment with cisplatin. Moreover, overexpression of CCN2 increased the resistance to cisplatin-mediated cell apoptosis. In contrast, reduction of CCN2 by CCN2 shRNA promoted the chemotherapeutic effect of cisplatin. We also found that CCN2 provided resistance to cisplatin-induced apoptosis through upregulation of Bcl-xL and survivin. Knockdown of Bcl-xL or survivin removed the CCN2-mediated resistance to apoptosis induced by cisplatin. On the other hand, CCN2 also promoted FAK, MEK, and ERK survival signaling pathways to enhance tumor survival during cisplatin treatment. In a mouse xenograft model, overexpression of CCN2 promoted resistance to cisplatin. However, knockdown of CCN2 increased the therapeutic effect of cisplatin. Therefore, our data suggest that CCN2 might be a critical oncogene of human osteosarcoma for cisplatin-resistance and supported osteosarcoma cell growth in vivo and in vitro.|
|Relation: ||PLoS One, 9(3):1.|
|Appears in Collections:||[生物科技學系] 期刊論文|
All items in ASIAIR are protected by copyright, with all rights reserved.